Cannabinoid Skin Research: Two Reviews and One Open Question
Definition
Cannabinoid skin research is the study of how cannabinoid receptors, the body's own cannabinoid-like molecules and the enzymes that clear them behave in skin tissue. The two papers cited here, from Bíró and colleagues in 2009 and Tóth and colleagues in 2019, are basic-science reviews: they gather cell-level and laboratory findings, not results measured in patients. That distinction decides what this page can say and where it stops.
Two reviews, one inventory
Two review papers sit behind this page, and neither one is a clinical trial. Bíró and colleagues published the first in 2009 [1]. Tóth and colleagues followed in 2019 [2]. Both are basic-science reviews, which means they collect laboratory and cell-level findings rather than outcomes measured in people. Psoriasis is classified in that literature as a chronic immune-mediated skin disease, involving cell growth, cell differentiation and immune signalling rather than the surface alone [1]. So this file has three jobs. Set out what the science currently holds. Describe what a convincing clinical study would have to look like. Leave you with questions worth asking in a dermatology consulting room. It is not a shopping list.
| Element named | Where it appears | In plain terms |
|---|---|---|
| The skin endocannabinoid system | Bíró and colleagues, 2009 [1] | A signalling system present in skin tissue itself: receptors, the body's own messenger molecules, and enzymes that break those messengers down again. |
| Cannabinoid receptors | 2009 review [1] | Receptor proteins that cannabinoid molecules can bind to. The review maps where in skin they were found. |
| The TRPV1 channel | 2009 review [1] | A related target counted in the same map. An ion channel, not a cannabinoid receptor, but part of the picture the authors assembled. |
| Keratinocytes | 2009 review [1] | The cells that make up most of the epidermis, the outer layer you can see and touch. |
| Sebaceous gland cells | 2009 review [1] | The cells of the oil-producing glands attached to hair follicles. |
| Resident immune cells | 2009 review [1] | Immune cells that live in skin rather than arriving from the bloodstream when something happens. |
| Cutaneous nerve fibres | 2009 review [1] | The nerve endings running through skin. Another site listed in the same mapping work. |
| Anandamide and 2-AG | 2009 review [1] | Two endocannabinoids, meaning cannabinoid-like molecules the body produces itself, described in the tissue rather than applied to it. |
| Fatty acid amide hydrolase, monoacylglycerol lipase | 2009 review [1] | The two enzymes named as the route by which those molecules are broken down. A signalling system needs an off switch as well as an on switch. |
| Cell division, maturation, immune signal exchange | Tóth and colleagues, 2019 [2] | Skin processes in which cannabinoid signalling is described as one system among several, rather than the one in charge. |
| Chronic immune-mediated skin disease | 2009 review [1] | The category psoriasis is grouped into: growth, differentiation and immune signalling together, not a surface problem. |
Seven conditions for a clinical answer
Say someone wants to attach a claim about cannabidiol to a chronic skin condition. The distance between two basic-science reviews and that claim is easiest to see when you describe the study that would close it. Nothing exotic is required. Standard clinical design, applied to this question.
- A defined population. Who is actually in the study. Same diagnosis, established the same way, with an agreed measure of how much skin is involved and how it was scored at the start. Without that boundary, a result describes an unsorted group of people and nobody can tell whom it applies to.
- A comparator. The study product is measured against something else rather than against itself. One arm receives the product under test, the other arm receives the comparator, and both arms are followed on the same schedule with the same assessments.
- Chance assignment. Which arm a participant lands in is decided by chance, not by the researcher's judgement, not by the participant's preference, not by the order people signed up. That is the only way the two groups start out comparable on everything the researchers did not think to measure.
- Blinded participants. People taking part do not know which arm they are in. Expectation is part of how anyone reads their own skin, so removing that knowledge removes one source of difference between the groups that has nothing to do with the product.
- Blinded assessors. The person scoring the skin does not know either. An assessor who knows which arm a participant is in is scoring with information that has no place in the measurement, and that shows up in the numbers.
- Enough time to survive the cycle. The clinical course is cyclical, with quiet stretches and flares, which is precisely why one before-and-after observation carries so little weight [1]. Two photographs six weeks apart can record a quiet stretch that would have arrived anyway.
- A published result to summarise. This is the section this page does not contain: a paragraph reporting trial outcomes. Neither cited review supplies one, because neither was designed to [1] [2]. When controlled trials in this area are published, that paragraph gets written and this file gets updated.
Where the record stops
Read side by side, the two reviews produce a clear split. Some questions have answers on paper. One does not. Both papers are worth taking seriously for what they are: real observations, narrowly scoped, made at the level of cells and tissue [1] [2].
| Question | What the cited work holds | Status |
|---|---|---|
| Does skin carry cannabinoid receptors? | Mapped in the 2009 review, together with related targets including the TRPV1 channel [1] | Documented, at cell and tissue level |
| Does skin produce its own cannabinoid molecules? | Anandamide and 2-AG are named, alongside fatty acid amide hydrolase and monoacylglycerol lipase [1] | Documented |
| Which cell types are involved? | Keratinocytes, sebaceous gland cells, resident immune cells and cutaneous nerve fibres [1] | Documented |
| How important is cannabinoid signalling in skin? | The 2019 review positions it as one of several systems in cell division, maturation and immune signal exchange [2] | Documented, and deliberately unranked |
| Do either of these papers measure outcomes in people with psoriasis? | Both are basic-science reviews, not clinical studies [1] [2] | Outside their design |
| Is there a controlled trial behind a cannabidiol claim for this condition? | Neither cited paper reports one [1] [2] | Open |
| What does cannabidiol's status look like in a cosmetic? | It is regulated as an ingredient; a cosmetic product is not required to run clinical trials, and the category carries no route to a medical claim | A regulatory fact, not evidence about skin disease |
| What would move this page? | Publication of controlled trials in this area | Pending |
Notes worth taking to a dermatologist
The clinical question is open. That is not a polite way of saying no, and it is not a hint either. It means the mapping work exists and the human trial does not, and the honest thing is to say so in one sentence rather than dress it up in five [1] [2].
We have worked with cannabinoids since 2014, long enough to watch a research field grow from almost nothing. It has not changed how this file reads. A mapped receptor is a mapped receptor. What happens to one person's skin over a year of quiet stretches and flares is a different question, and it belongs to the clinician who knows that person's history [1].
If an appointment is coming up, arriving with things written down makes the twenty minutes go further. Worth putting on one sheet of paper:
- The diagnosis as it is written in your records, and who made it. A defined starting point is the same thing a clinical study needs before it can measure anything.
- Dates. When flares started, roughly how long each quiet stretch lasted, what the pattern looked like over the last year, since the course is described as cyclical in the literature [1].
- Everything currently prescribed, copied from the packaging: names, strengths, how often, since when. Reading it off the box beats reconstructing it from memory in the room.
- Everything currently applied to skin, cosmetic products included, with the ingredient list. Cannabidiol in a cosmetic sits on that list as a regulated ingredient, which is exactly where a clinician would look for it.
- One direct question about human evidence: for this specific condition, is there a controlled trial, and what did it actually measure.
- Whether anything new should go near affected areas at all, and who makes that call. That is a clinical decision, not a shelf decision.
- Which scoring measure the clinic uses for severity, so the next appointment compares like with like instead of two impressions months apart.
- What would count as a reason to come back sooner, and how that message reaches the practice.
Frequently Asked Questions
3 questionsWhat did the 2009 review by Bíró and colleagues actually map?
Why is a before-and-after photo not enough here?
How is cannabidiol handled when it appears in a cosmetic?
About this article
Luke Sholl has been writing about cannabinoids, CBD, and the broader benefits of nature since 2011. His background includes first-hand cannabis cultivation experience spanning the full seed-to-harvest lifecycle across so
This wiki article was drafted with AI assistance and reviewed by Luke Sholl, CBD & wellness writer. Editorial oversight by Joshua Askew.
Medical disclaimer. This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before use of any substance.
Last reviewed August 27, 2026
References (2)
- [1]Bíró, T. et al. (2009). Trends in Pharmacological Sciences. DOI: https://doi.org/10.1016/j.tips.2009.05.004
- [2]Tóth, K.F. et al. (2019). Molecules. DOI: https://doi.org/10.3390/molecules24050918
Related Articles
Can You Be Allergic to CBD? Two Papers, One Protein
Two published papers characterise a cannabis plant protein called Can s 3 as an allergen. Here is what they cover, what they leave open, and where the carrier oil and softgel shell fit in.
CBD and Ibuprofen: One Shared Liver Enzyme
Ibuprofen depends on a single liver enzyme, and cannabidiol has been described as an inhibitor of it. Here is what the 2011 and 2019 research documented, and where the record simply stops.
CBD That Mixes Into Water: The Actual Chemistry
The phrase exists because of one physical fact: cannabidiol and water do not mix on their own. Here is what emulsions and liposomes actually are, and where the published human measurements stop.
CBD Oil or Gummies: Where the Amount Gets Decided
The pipette leaves the counting to you; the gummy carton arrives with the number already on it. Here is what the published human data covers, and where it stops.
One Gummy, 25 mg, and What the Studies Measured
25 mg per gummy, ten in a pack, THC-free printed on the box. What happens after chewing is the part human trials are still measuring [1].
Travelling With CBD: Check Three Countries First
A country-by-country permission list for CBD is wrong by design. Here is the checking order instead: three countries per ticket, the airline's own conditions, and a clear rule for unresolved cases.
What Is A CBD Tincture? The Word And The Bottle
Tincture once described a method: extraction with alcohol. Here is how the word travelled to CBD dropper bottles, and what the ingredient list settles that the front label does not.
Combining CBD Products: Counting The Day's Milligrams
An oil in the morning and a capsule at night belong to the same daily figure, counted in milligrams. Here is how that arithmetic works, what the human pharmacokinetic literature covers, and why a topical sits in a column of its own.
Ways To Take CBD, Route By Route
A pipette bottle, a capsule and a chewable piece are not three sizes of the same thing. They sit on different routes, and published human reviews keep those routes in separate columns.
